Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies.
Latest Information Update: 10 Nov 2015
Price :
$35 *
At a glance
- Drugs Alemtuzumab (Primary) ; Clofarabine (Primary) ; Melphalan (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Lymphoid leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions
- 09 Jul 2012 Planned End Date changed from 1 Dec 2016 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 09 Jul 2012 Planned End Date changed from 1 Dec 2016 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 25 Jun 2012 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.